Cellectar Biosciences Statistics
Total Valuation
CLRB has a market cap or net worth of $8.89 million. The enterprise value is -$14.16 million.
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLRB has 10.04 million shares outstanding. The number of shares has increased by 394.50% in one year.
| Current Share Class | 10.04M |
| Shares Outstanding | 10.04M |
| Shares Change (YoY) | +394.50% |
| Shares Change (QoQ) | +42.77% |
| Owned by Insiders (%) | 1.73% |
| Owned by Institutions (%) | 33.03% |
| Float | 7.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.44 |
| Quick Ratio | 4.24 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -162.63% and return on invested capital (ROIC) is -99.18%.
| Return on Equity (ROE) | -162.63% |
| Return on Assets (ROA) | -75.46% |
| Return on Invested Capital (ROIC) | -99.18% |
| Return on Capital Employed (ROCE) | -111.86% |
| Weighted Average Cost of Capital (WACC) | 6.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.35M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.68% in the last 52 weeks. The beta is 0.63, so CLRB's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -69.68% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 25.05 |
| Average Volume (20 Days) | 87,642 |
Short Selling Information
The latest short interest is 218,774, so 2.18% of the outstanding shares have been sold short.
| Short Interest | 218,774 |
| Short Previous Month | 263,517 |
| Short % of Shares Out | 2.18% |
| Short % of Float | 2.89% |
| Short Ratio (days to cover) | 1.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.78M |
| Pretax Income | -25.85M |
| Net Income | -25.85M |
| EBITDA | -26.63M |
| EBIT | -26.78M |
| Earnings Per Share (EPS) | -$2.71 |
Full Income Statement Balance Sheet
The company has $24.58 million in cash and $1.53 million in debt, with a net cash position of $23.05 million or $2.30 per share.
| Cash & Cash Equivalents | 24.58M |
| Total Debt | 1.53M |
| Net Cash | 23.05M |
| Net Cash Per Share | $2.30 |
| Equity (Book Value) | 22.42M |
| Book Value Per Share | 2.23 |
| Working Capital | 19.92M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$24.61 million and capital expenditures -$9,258, giving a free cash flow of -$24.62 million.
| Operating Cash Flow | -24.61M |
| Capital Expenditures | -9,258 |
| Depreciation & Amortization | 155,268 |
| Net Borrowing | n/a |
| Free Cash Flow | -24.62M |
| FCF Per Share | -$2.45 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -394.50% |
| Shareholder Yield | -394.50% |
| Earnings Yield | -305.93% |
| FCF Yield | -277.06% |
Analyst Forecast
The average price target for CLRB is $11.50, which is 1,199.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.50 |
| Price Target Difference | 1,199.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on June 24, 2025. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jun 24, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |